Editorial stack guide · Longevity
Longevity: Epitalon, MOTS-c, NAD precursors
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Longevity stack
Epitalon, MOTS-c and NAD precursors (NR and NMN) sit at three distinct corners of the longevity research literature: the pineal-pituitary axis, mitochondrial-derived peptide signalling, and cellular NAD+ metabolism. Each has its own evidence base, regulatory status and UK availability route. None constitutes a proven anti-ageing intervention. PeptideClear publishes encyclopedia commentary only. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber.
Compounds in the longevity-research conversation
Three mechanistically distinct compound classes appear in longevity discussions. Epitalon is a Russian-research tetrapeptide. MOTS-c is a mitochondrial-derived peptide. NAD precursors (NMN, NR) are pyridine nucleotide precursors rather than peptides. Treat them as three separate research lines that share a longevity framing rather than a unified protocol.
Epitalon
Evidence: Mixed evidenceEpitalon (also written Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the Khavinson group at the St Petersburg Institute of Bioregulation and Gerontology. The Russian research lineage spans four decades and covers pineal-axis regulation, melatonin output, telomere-length endpoints in cell culture, and lifespan endpoints in rodent studies. Russian clinical work in older adults reports effects on melatonin secretion patterns and cardiovascular markers. Independent Western replication of the headline lifespan claims is sparse.
Encyclopedia entry for Epitalon ·MOTS-c
Evidence: Animal onlyMOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Discovered by the Cohen group at the University of Southern California in 2015. Research describes effects on AMPK signalling, insulin sensitivity, and metabolic homeostasis in animal models of ageing and obesity. The compound represents a class of mitochondrial-derived peptides that signal between mitochondria and the wider cellular metabolic network. No published human clinical trials.
Encyclopedia entry for MOTS-c ·NAD precursors (NR and NMN)
Evidence: Mixed evidenceNicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are small molecules, not peptides. Both serve as precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme used by sirtuins, PARPs and other NAD+-dependent enzymes whose activity declines with age. Human trial work on NR is more developed than on NMN. Reported effects on NAD+ pool restoration are measurable. Downstream effects on age-related endpoints in humans remain less well characterised.
What the literature shows
The Epitalon literature, anchored on the Khavinson group, describes pineal-axis regulation, increased melatonin secretion, and effects on telomere length in cultured cells. Rodent lifespan studies from the originating research lineage report increases in median and maximum lifespan. The published work is mostly in Russian-language journals, with some translated reviews available in English. The principal interpretive challenge is the absence of independent Western replication at the scale needed to settle the headline claims.
MOTS-c research is younger and centred on the Cohen group and collaborators. The literature describes AMPK pathway activation, improved insulin sensitivity, and protective effects in rodent models of high-fat-diet metabolic dysfunction. The conceptual contribution of the MOTS-c literature is the demonstration that the mitochondrial genome encodes peptides that signal at the cellular and systemic level. Human trial data is not yet published.
NAD precursor research has produced human RCT data for NR (the Brenner group at the University of Iowa, the Trammell trial, the Martens trial). Trials describe restoration of NAD+ pools, modest effects on cardiovascular markers, and acceptable safety at doses studied (typically 250 to 1000 mg daily). NMN human data is more recent. Sirtuin and PARP biology provides the mechanistic rationale, but translating restored NAD+ pools into measurable changes in age-related endpoints remains an open research question.
What we do not know
- · Whether Epitalon extends human lifespan or healthspan at any dose, by any route of administration.
- · Whether the Russian lifespan findings in rodents reproduce in independent Western laboratories.
- · Whether MOTS-c effects observed in rodent metabolic models transfer to humans in any endpoint.
- · Whether NAD+ pool restoration via NR or NMN translates to measurable changes in age-related disease incidence or functional endpoints.
- · Long-term safety of Epitalon or MOTS-c in humans at any dose, including immunogenicity and effects on undiagnosed neoplastic tissue.
- · Whether combining Epitalon, MOTS-c and an NAD precursor produces additive, synergistic or null effect versus any one alone.
- · Whether higher-dose NMN supplementation carries risks not captured in current short-duration trial data.
UK regulatory framing
Epitalon
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Sold by a subset of UK research peptide retailers under research-use-only framing. Counterfeit risk is meaningfully higher than for mainstream research peptides because Epitalon sits in a thinner supply chain.
MOTS-c
Same UK position as Epitalon. No MoDA or PSA listing. No MHRA marketing authorisation. Sold by UK research peptide retailers under research-use-only framing. Not stocked by UK clinics or pharmacies in any licensed clinical context.
NAD precursors
NR has established status as a food supplement ingredient in the UK following retained EU novel food authorisation. NMN sits in an unsettled position: the FSA has not authorised it under the retained novel food regulation as of the date on this page. Products sold operate in a regulatory grey area. Status may change as the FSA updates its novel food list.
How a UK practitioner would discuss this
A UK private longevity clinician approaching this conversation will typically anchor on baseline assessment first. That means cardiometabolic biomarkers, body composition, sleep, activity, and where indicated genomic or epigenetic measurement. The interventions that hold up best across the longevity-medicine evidence base are not peptides: structured resistance and cardiorespiratory training, dietary pattern, sleep quality, and the small number of pharmaceuticals (metformin, rapamycin, GLP-1 agonists) under active clinical-trial investigation in ageing endpoints.
Research peptides occupy a separate conversation within private longevity practice. A UK-registered prescriber discussing Epitalon or MOTS-c would frame them as research compounds without UK marketing authorisation, without established human efficacy data, and without integration into mainstream longevity-medicine pathways. Some private clinicians offer them; many do not. The variation reflects the evidence gap, not a settled clinical position.
NAD precursors sit between the two conversations. NR has enough human trial data to support a measured discussion as a food supplement with reasonable safety at studied doses, while acknowledging that translation to age-related health endpoints remains an open question.
Where to learn more
- · Encyclopedia entry: Epitalon
- · Encyclopedia entry: MOTS-c
- · Retailer comparison: Best UK MOTS-c retailers
- · Clinic comparison: Best UK longevity clinics
- · Glossary: peptide terminology reference
- · Research peptides hub: all UK research peptide entries
Frequently asked questions
Is Epitalon clinically proven?
Are NMN and NR the same thing?
Is NMN legal to sell in the UK?
Are these compounds part of NHS longevity care?
Should I combine all three?
PeptideClear publishes encyclopedia commentary only. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber. Epitalon and MOTS-c are sold under research-use-only framing. NR is a food supplement. NMN sits in an unsettled UK regulatory position.
Read our full methodology and how we are funded.
Ready to buy
Shop UK peptides, collagen and GLP-1 routes
Compare UK retailers, clinics and pharmacies across every PeptideClear category.